171 related articles for article (PubMed ID: 29057423)
21. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases.
Aasi S; Silkiss R; Tang JY; Wysong A; Liu A; Epstein E; Oro AE; Chang AL
JAMA Dermatol; 2013 Feb; 149(2):242-3. PubMed ID: 23426496
[No Abstract] [Full Text] [Related]
22. Trichodysplasia spinulosa in gorlin syndrome treated with vismodegib.
Lopez-Lerma I; Mollet J; Garcia-Patos V
JAMA Dermatol; 2015 Apr; 151(4):458-9. PubMed ID: 25471402
[No Abstract] [Full Text] [Related]
23. Trichodysplasia spinulosa in gorlin syndrome treated with vismodegib-reply.
Richey JD; Katona T; Travers JB
JAMA Dermatol; 2015 Apr; 151(4):459. PubMed ID: 25471598
[No Abstract] [Full Text] [Related]
24. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
25. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma.
Orouji A; Goerdt S; Utikal J; Leverkus M
Br J Dermatol; 2014 Aug; 171(2):431-3. PubMed ID: 24446722
[No Abstract] [Full Text] [Related]
26. Four-year experience with vismodegib hedgehog inhibitor therapy.
Simone PD; Schwarz JM; Strasswimmer JM
J Am Acad Dermatol; 2016 Jun; 74(6):1264-5. PubMed ID: 27185433
[No Abstract] [Full Text] [Related]
27. Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma.
Dessinioti C; Plaka M; Dimitrakopoulou A; Stratigos AJ
J Eur Acad Dermatol Venereol; 2019 May; 33(5):e187-e188. PubMed ID: 30653740
[No Abstract] [Full Text] [Related]
28. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
Demirci H; Worden F; Nelson CC; Elner VM; Kahana A
Ophthalmic Plast Reconstr Surg; 2015; 31(6):463-6. PubMed ID: 25675162
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
[TBL] [Abstract][Full Text] [Related]
31. Vismodegib (ERIVEDGE°) In basal cell carcinoma: too many unknowns.
Prescrire Int; 2015 Jan; 24(156):11-4. PubMed ID: 25729822
[TBL] [Abstract][Full Text] [Related]
32. Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient.
Koelblinger P; Dummer R; Laimer M; Hecht S; Bauer JW; Gaggl A; Kugler A
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e7-e8. PubMed ID: 28646606
[No Abstract] [Full Text] [Related]
33. Vismodegib in the treatment of advanced BCC.
O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM
Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719
[TBL] [Abstract][Full Text] [Related]
34. Cannabis for Vismodegib-Related Muscle Cramps in a Patient With Advanced Basal Cell Carcinoma.
Kutiel TS; Vornicova O; Bar-Sela G
J Pain Symptom Manage; 2018 May; 55(5):e1-e2. PubMed ID: 29454899
[No Abstract] [Full Text] [Related]
35. Vismodegib in real-life clinical settings: A multicenter, longitudinal cohort providing long-term data on efficacy and safety.
Apalla Z; Spyridis I; Kyrgidis A; Lazaridou E; Kyriakou A; Fotiadou C; Pikou O; Sotiriou E; Vakirlis E; Papageorgiou C; Delli F; Moutsoudis A; Manoli SM; Ioannides D; Lallas A
J Am Acad Dermatol; 2021 Dec; 85(6):1589-1592. PubMed ID: 33253837
[No Abstract] [Full Text] [Related]
36. Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient.
Cusack CA; Nijhawan R; Miller B; Henien M; Malat G; Doyle A; Abdelmalek M
JAMA Dermatol; 2015 Jan; 151(1):70-2. PubMed ID: 25337679
[TBL] [Abstract][Full Text] [Related]
37. [A new drug for basal cell carcinoma].
Witte F
Schweiz Monatsschr Zahnmed; 2013; 123(12):1104-6. PubMed ID: 24730087
[No Abstract] [Full Text] [Related]
38. Gorlin Syndrome, Vulvar Basal Cell Carcinomas, Vismodegib, and Lichen Sclerosus: From the ISSVD Case Consultation Committee.
Kirkpatrick E; Dobriansky D; Scurry J
J Low Genit Tract Dis; 2016 Jul; 20(3):e40-1. PubMed ID: 27105331
[No Abstract] [Full Text] [Related]
39. Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.
Fife K; Herd R; Lalondrelle S; Plummer R; Strong A; Jones S; Lear JT
Future Oncol; 2017 Jan; 13(2):175-184. PubMed ID: 27640448
[TBL] [Abstract][Full Text] [Related]
40. Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp.
Tauber G; Pavlovsky L; Fenig E; Hodak E
J Am Acad Dermatol; 2015 Nov; 73(5):799-801. PubMed ID: 26320385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]